340B Drug Pricing Program
AHA statement on HRSA ordering drug companies to restore 340B discounts on drugs dispensed at community pharmacies
The AHA expresses support for legislation H.R. 3203 introduced in the House that would provide certainty to hospitals participating in the 340B Drug Pricing Program during the COVID-19 public health emergency.
IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE
ASTRAZENECA PHARMACEUTICALS LP,
Plaintiff,
v.
XAVIER BECCERA, et al.,
Defendants.
CASE NO.: 1:21-CV-00027-LPS
ºÚÁÏÕýÄÜÁ¿ Association, 340B Health, America’s Essential Hospitals, Association of American Medical Colleges, National Association of Children’s Hospitals d/b/a Children’s Hospital Association, and American Society of Health-System Pharmacists, by and through their undersigned attorneys,…
The AHA and five other health care organizations today sent a letter to Health and Human Services Secretary Xavier Becerra urging him to stop the actions of six drug companies that are denying 340B discounts on prescription drugs sold to hospitals treating a large percentage of low-income and rural…
The leaders of six major organizations representing hospitals and pharmacists sent a letter to U.S. Health and Human Services (HHS) Secretary Xavier Becerra urging him to halt the actions of six drug companies that are denying 340B discounts on prescription drugs sold to hospitals treating a large…
The AHA and five other health care organizations sent the attached letter to HHS Secretary Becerra urging him to stop the actions of six drug companies that are denying 340B discounts on prescription drugs sold to hospitals treating a large percentage of low-income and rural Americans.
The AHA today urged the Department of Health and Human Services to ensure hospitals currently participating in the 340B Drug Pricing Program continue to have access to the program despite changes in their payer mix as a result of the COVID-19 public health emergency.
Motion and Memorandum in Support of Motion to Intervene NOVO NORDISK v Cochran (March 2, 2021)
AHA urges the Department of Health and Human Services (HHS) to ensure hospitals currently participating in the 340B Drug Pricing Program continue to have access to the program despite changes in their payer mix as a result of the COVID-19 public health emergency (PHE).